INVO Bioscience Completes Reverse Merger ( Shares trading under IVOB symbol on O...)

INVO Bioscience Completes Reverse Merger

Date:2/25/2009

Shares trading under IVOB symbol on OTCBB

BEVERLY, Mass., Feb. 25 /PRNewswire-FirstCall/ -- INVO Bioscience, Inc. ("INVO Bioscience" or "the company"), focused on creating simplified, lower cost treatment option for patients diagnosed with infertility, announced the closing of its reverse merger with Emy's Salsa Aji Distribution Company, Inc. (OTC Bulletin Board: EMYS.OB). Through this transaction, INVO Bioscience, formerly BioXcell becomes a public reporting company and its common stock is listed on the OTCBB under the newly-assigned symbol (OTC Bulletin Board: IVOB). The INVO Bioscience executive team will operate the new company focusing on INVOcell sales globally.

"This is a significant step in the growth of our company," said Kathleen Karloff, Chief Executive Officer of INVO Bioscience. "We are now positioned to execute our vision of providing an innovative, more affordable infertility treatment option to the millions of infertile men and women around the world".

"The INVOcell is a novel medical device that enables egg fertilization and early embryo development in the woman's vaginal cavity. The INVO Procedure will be an important option for patients who cannot afford conventional infertility treatments, enabling more patients to seek treatment and build families," added Claude Ranoux, MD, MS, Founder, President and Chief Scientist, INVO Bioscience.

For additional information about this transaction, see the company's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on February 17, 2009 at www.sec.gov.

About the INVOcell Procedure

The INVOcell and INVO Procedure combine a natural or mild stimulation infertility treatment cycle, using lower amounts of injectable fertility hormones than used in traditional IVF(in vitro fertilization), with intra-vaginal incubation
'/>"/>

SOURCE INVO Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
7. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada

Post Your Comments:

(Date:5/16/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... http://www.reportlinker.com/p090668/Global-Biotechnology-Instrumentation-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_ This ... Biotechnology Instrumentation in US$ Million by ... Protein/Peptide Synthesizers, DNA Sequencers, Protein/Peptide Sequencers, ...

(Date:5/16/2012)... WOONSOCKET, R.I., May 16, 2012 MultiCell ... MCET ) is pleased to announce representatives ... findings for MCT-465 and MCT-485 at CIMT ... dedicated to cancer immunotherapy research and development. ... 23-25 in Mainz, Germany. The title of ...

(Date:5/15/2012)... Vermillion, Inc. (NASDAQ: VRML ), ... results for the first quarter ended March 31, 2012. ... In Q1, the volume of OVA1®, the company,s flagship ... ovarian masses, was generally in line with the forecast ... increase of 28% to 3,952 from the same year-ago ...

(Date:5/15/2012)... -- Cardium Therapeutics (NYSE Amex: CXM ... first quarter ended March 31, 2012, and other ... In addition to the announcement ... its goals for 2012, which were outlined in ... advance commercialization of its new Excellagen® advanced, physician-use ...

[0] Global Biotechnology Instrumentation Industry [0] MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models [0] Vermillion Reports First Quarter 2012 Results [0] Cardium Presents First Quarter 2012 Financial Results and Recent Developments

... Neurological Function Now Available in the US, ... a new product called NeuroAid10(TM) in the US ... from,NeuroAid(TM) and is a combination of ten all-natural ... together the best of Asian,and Western medicine., ...

... Calif., March 6 Senetek PLC (OTC,Bulletin Board: ... development,of technologies that target the science of healthy ... two Veteran Sales and Marketing Executives,and the appointment ... Campagnoli joined the Company in December and has ...

... Inc., a,biodefense company specializing in the development and ... announced,today that it has completed the initial pharmacokinetic ... nerve agent prophylaxis., The PK studies were ... final,pegylated version of rBChE for the first time. ...

Other Biology Technology:Moleac Launches NeuroAid10(TM) in the United States 2 Moleac Launches NeuroAid10(TM) in the United States 3 Senetek PLC Announces Appointments of Key Personnel 2 Senetek PLC Announces Appointments of Key Personnel 3 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 2 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 3 PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 4

Moleac Launches NeuroAid10(TM) in the United States Senetek PLC Announces Appointments of Key Personnel PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008

(Date:5/21/2012)... US scientists has found there has been a massive ... off the coast of Antarctica.,Comparing detailed measurements taken during ... voyage to historical data dating back to 1970, scientists ... per cent reduction in the volume of Antarctic Bottom ... currents. , In an intensive and arduous 25-day observing ...

(Date:5/20/2012)... ARLINGTON, VA (May 14, 2012) - ... groundbreaking research being unveiled at the American Association ... The conference takes place Monday, May 21 - ... Hotel and Marina. Other topics to be discussed ... and tech transfer strategies, applications of multi-scale systems ...

(Date:5/20/2012)... uses a trial-and-error process to mimic the song of its ... times a day, making subtle changes in the pitch of ... process begins around the age of 40 days and is ... and ready to use his song to woo females. , ... process large quantities of information about its performance and use ...

Breaking Biology News(10 mins):Latest Southern Ocean research shows continuing deep ocean change 2 Latest Southern Ocean research shows continuing deep ocean change 3 AAPS National Biotechnology Conference to highlight innovative vaccines 2 Songbirds' learning hub in brain offers insight into motor control 2 Songbirds' learning hub in brain offers insight into motor control 3 Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference 11873 1 Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference 11873 2 iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 1 iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 2 iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 3 Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 1 Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 2 Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 3

[0] Latest Southern Ocean research shows continuing deep ocean change [0] AAPS National Biotechnology Conference to highlight innovative vaccines [0] Songbirds' learning hub in brain offers insight into motor control

... research in an animal model suggests that a diet ... variety of processed foods including meats, cheeses, beverages, and ... and may even contribute to the development of those ... study also suggests that dietary regulation of inorganic phosphates ...

... 12 WCC Smart Search & Match,the leading ... that Rudie Lion has joined the company as ... brings more than 15 years of product and ... market introduction efforts,for many high-tech products and solutions ...

... can halt the might of a tsunami are false and ... There are many reasons for preserving the world,s dwindling stocks ... of them, they say. , On the eve ... which claimed nearly a quarter of a million lives around ...

Other Biology News:Common food additive found to increase risk and speed spread of lung cancer 2 Common food additive found to increase risk and speed spread of lung cancer 3 Trees won't stop tsunamis, scientists warn 2 Trees won't stop tsunamis, scientists warn 3

Common food additive found to increase risk and speed spread of lung cancer WCC Smart Search and Match Names Rudie Lion - Product Marketing Manager Trees won't stop tsunamis, scientists warn

... The Tetrad 2 thermal cycler is a ... original Tetrad chassis, and it accepts the ... It delivers the same precision in thermal ... original Tetrad thermal cyclers, allowing easy transport ...

... The new Pierce ready-to-use 2-D gel marker ... analyst. This 2-D gel marker mix contains a ... offer important features of value to those who ... estimate pI and molecular weight values of proteins ...

... Tetrad thermal cycler expands the envelope ... DNA Engine cycler. It ... a footprint only twice the size, ... that run massive quantities of reactions, ...

The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....

Biology Products:

DNA Engine Tetrad 2 Peltier Thermal Cycler, w/4 x 384-well blocks & motorized lid from Bio-Rad 2-D MARKER from Pierce Biotechnology, Inc.DNA Engine Tetrad 2 Peltier Thermal Cycler, w/4 x 384-well blocks from Bio-Rad Sealed Ice Blocks, for Criterion blotter, 2 from Bio-Rad

INVO Bioscience Completes Reverse Merger( Shares trading under IVOB symbol on O...)